anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention relates to medical microbiology. Described is a method for producing an antigenic conjugated substance of a haemophilic type b microbe for creating a haemophilic type b conjugate vaccine (Hib), as well as combined vaccines containing ADS + Hib, DTaP + Hib. Haemophilus influenzae type b (Hib) No. B-7519 strain is cultured on chocolate agar with addition of bacitracin and subsequent transfer to a liquid nutrient medium of the following composition: hydrochloric acid hydrolyzate of casein, glucose, yeast extract, nicotinamide dinucleotide (NAD), hemin, group B vitamins, NaHPO4, KH2PO4.Culture is inactivated by treating it with 0.1 % formaldehyde. Further, Hib cells are separated from the culture fluid by filtration on plate membrane filters in a tangential flow. When isolating capsular polysaccharide (CP) Hib, cetyltrimethylammonium bromide (cetavlone) is used, wherein the amount of cetavlone is calculated taking into account the content of CP in the concentrate by formula: mC = Px48, where mC is the amount of cetavlone, Ρ is the amount of phosphorus in the volume of the ultrafiltrate concentrate, 48 is the conversion factor. CP is cleaned by hot phenol treatment with subsequent alcohol deposition. For the conjugation step, tetanus anatoxin is used, activating it by a carbodiimide method, attaching a linker molecule ADH (adipic acid dihydrazide) to it. Conjugation is carried out by adding to activated tetanus toxoid purified capsular polysaccharide Hib treated with a cyanylating agent.EFFECT: invention enables to create an antigenic conjugated substance of a haemophilic type b microbe for producing a haemophilic type b conjugate vaccine (Hib), as well as combined vaccines containing ADS + Hib, DTaP + Hib.7 cl, 8 dwg, 1 ex
This study aims to (1) iteratively develop and program a theoretically informed technology-based nudge message library for a diverse patient population using multiple and iterative N of 1 within subject studies. Investigators will also engage patient, provider and health systems stakeholders in designing and refining the messages. (2)Develop a one-page decision aid tool to present information designed with principles of shared decision making including pros and cons of hospital and home-based rehabilitation. Investigators will engage patients, providers, and health systems stakeholders to provide feedback on the information sheet. (3) Conduct a 2x2 factorial design randomized trial of a) choice and b) nudge messaging to improve primary outcome of CR adherence. Secondary outcomes will include enrollment and completion of CR, exercise capacity, patient engagement, quality of life, hospitalizations, and healthcare utilization. The study will additionally evaluate the interventions using a mixed methods approach applying the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework and a cost-effectiveness analysis. The cost-effectiveness analysis sub-study will evaluate the implementation cost of home-based and hospital-based cardiac rehabilitation programs in addition to the incremental cost effectiveness ratios for each intervention.
Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
* Start treatment with a dosage equal to ⅙ to ¼ of the maintenance dosage.
  * The maintenance dosage after initial dose escalation is 1.3 g/m2 of body surface area per day divided into two doses given every 12 hours. Table 1 shows the recommended starting and maintenance dosages of PROCYSBI, converted from body-surface area to body weight.
    * Patients 1 year to less than 6 years: Increase the dosage in 10% increments to the maintenance dosage, while monitoring WBC cystine concentrations. Allow a minimum of 2 weeks between dosage adjustments [see Dosage and Administration (2.4, 2.5)]. If a patient achieves the therapeutic target WBC cystine concentration at a dosage below the recommended weight-based maintenance dosage, then stop dosage escalation and use the dosage as the patient's maintenance dosage.
    * Patients 6 years of age and older: Gradually increase the dosage over 4 to 6 weeks until the maintenance dosage is achieved.
  * If a patient experiences initial intolerance, temporarily discontinue PROCYSBI and then re-start at a lower dosage and gradually increase dosage.
Duodenal Ulcer

In a U.S. multicenter, double-blind study in outpatients with endoscopically confirmed duodenal ulcer, orally administered famotidine was compared to placebo. As shown in , 70% of patients treated with Famotidine 40 mg h.s. were healed by week 4. Table 1

Patients not healed by week 4 were continued in the study. By week 8, 83% of patients treated with famotidine had healed versus 45% of patients treated with placebo. The incidence of ulcer healing with famotidine was significantly higher than with placebo at each time point based on proportion of endoscopically confirmed healed ulcers.

In this study, time to relief of daytime and nocturnal pain was significantly shorter for patients receiving famotidine than for patients receiving placebo; patients receiving famotidine also took less antacid than the patients receiving placebo.
Connective tissue massage will be applied to the lumbosacral, lower thoracic, abdominal and anterior pelvic regions 5 days a week, from the estimated date of ovulation until the onset of the next menstrual bleeding. The application will take approximately 15 minutes. During the massage, the physiotherapist will bring the tip of the middle finger of the hand into contact with the patient's skin and apply traction to the skin. During the treatment of the lumbar region, the patient will be in the sitting position, during the treatment of the abdominal and anterior pelvic region, the patient will be in the supine position.
The study is comparing current standard of care blood glucose fingersticks or serum blood glucose collection to CGM data utilizing the Freestyle Libre 2.0 CGM. A recently conducted study of 8 critically ill patients with diabetes that wore Freestyle Libre 2.0 CGM's during their ICU stay demonstrated high test-retest reliability and acceptable accuracy when compared with arterial blood glucose measurements. The study aims to evaluate utilization of CGM technology and EndoTool in the critical care setting by recruiting a cohort of 10 participants with hyperglycemia and/or diabetes mellitus who are anticipated to require blood glucose monitoring and IV insulin to achieve adequate glycemic control while in the Neuro ICU. The study also aims to evaluate utilization of CGM technology and subcutaneous insulin by recruiting a cohort of 10 patients with a history of diabetes mellitus on high dose steroids who are anticipated to require blood glucose monitoring and treatment with basal bolus insulin.

Participants will be enrolled on admission to the Neuro ICU and have the CGM device placed. The study aims to evaluate CGM technology by comparison of glucose values obtained from the CGM to the serum or fingerstick blood glucose levels while the patient is either receiving IV insulin via EndoTool or subcutaneous insulin while on high dose glucocorticoids. Current standard of care with monitoring glycemic data utilizing point of care blood glucose fingersticks and serum glucose will be utilized for comparison.
Invention concerns a procedure for production of d-form of 3-oxo-17β-hydroxy-17α-ethynyl-13β-ethyl-4-gonen with the general formula given in the claim's introduction D or esters thereof with 1-18 carbon atoms, and this procedure is distinguished as described in the clam's listing of characteristics. According to the invention, the base product in the procedure is a decomposed product. Use of a decomposed product in a particular step of a synthesis is of great economic interest. The ethynylation step presents a surprising character. In reality one might expect after the known technique and notably USA patent documents no. 2,962,509, column 1, lines 50-59, ethynylation of the ketone group in the 3-position.
Background. Lung carcinoma with p40/TTF1 coexpression (LC-PTC) is a very rare tumor with poor prognosis, and few cases have been reported to date. Objectives. To better understand biological behavior and prognosis of LC-PTC. Methods. We collected 9 examples of LC-PTC and compared them with 36 lung adenosquamous carcinomas during the same period in clinicopathologic characteristics, biologic behaviour, and prognosis. Results. Lung carcinoma with p40/TTF1 coexpression mainly occurred in middle-aged and elderly men; 8 tumors belonged to the peripheral type, and 1 belonged to the central type. The rates of lymph node and distant metastasis were 88% (7/8) and 50% (4/8), respectively; 2 patients died during follow-up. Histologically, the LC-PTC showed nest-like growth pattern without glandular growth pattern; the surface of 2 tumors was covered with ciliated columnar epithelium and tumor cells grew under the columnar epithelium. In all patients, tumor cells diffusely coexpressed p40 and TTF1. Although there was no significant difference in the maximum diameter of tumor with lymph node metastasis or with distant metastasis between LC-PTC and lung adenosquamous carcinoma, LC-PTC had a higher rate of lymph node metastasis and distant metastasis. There was no significant difference in overall survival of patients between LC-PTC and lung adenosquamous carcinoma. Additional histologic evaluation of normal pulmonary structures revealed that p40/TTF1 coexpression cells existed in bronchial mucosa and the number of cells coexpressing p40/TTF1 increased gradually from proximal bronchus to distal bronchus. Conclusions. Lung carcinoma with p40/TTF1 coexpression is a rare tumor with high metastatic potential and may originate from p40/TTF1 coexpression cells in distal bronchial mucosa.
NEW MATERIAL:A lymphokine produced by human B cell, a human B cell differentiation factor (BCDF) having the following properties. Molecular weight: 15,000-30,000. Isoelectric point: 5-5.5. Heat stability: >=90% human B cell differentiation factor activity remains by treatment at about neutrality at 50 deg.C for 30min (>=90% activity disappears by treatment at 80 deg.C for 15min). pH Stability: >=90% activity remains by treatment at 25 deg.C at 2pH for 30min. Trypsin treatment: activity is reduced. USE:BCDF antibody is prepared from BCDF, and used for immunological pathological analysis by the use of immunoassay. BCDF is useful for remedy and diagnosis of various diseases, for example, it is administered to a patient of immune incompetence so that mechanism of antibody production is restored to a normal state. PREPARATION:Lymphocyte is separated from human peripheral blood or amygdala by density-gradient centrifugation, etc., human B cell is transformed by the use of EVB, a cell strain B of BCDF preparation is established, and it is cultivated to obtain human BCDF.
A nanometer antibody sequence for resisting H9 subtype avian influenza virus, an expression engineering strain and a preparation method thereof relate to the field of biology, and the invention screens an H9 subtype avian influenza resisting antibody from an established VHH phage library of an immune alpacaThe variable region sequence of the heavy chain antibody of the influenza virus has a nucleotide sequence of SEQ ID NO. 1 and an encoded amino acid sequence of SEQ ID NO. 2. The sequence is directionally cloned into eukaryotic expression plasmid pPIC9K to construct recombinant eukaryotic expression plasmid, and the recombinant eukaryotic expression plasmid is transformed into Pichia pastoris expression system to screen expression engineering strain, and the recombinant nanobody is obtained after methanol induction, supernatant collection and affinity chromatography purification. The recombinant nanobody has a yield of 3.5mg/L and a neutralization activity titer of 4log against H9 subtype avian influenza virus  2  Has remarkable biological activity and can be used for preventing and/or treating H9 subtype avian influenza. The preparation method of the invention has simple operation and low cost, and is suitable for mass production.
Functional constipation patients maintained at least 3 months of continuous regular therapy with effective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
A system and method for dynamic risk assessment is disclosed. The system may include a data warehouse, an output device and a processor including a data capturer, a process engine and a rules engine. The data capturer may capture information pertaining to a plurality of risk factors associated with an infection risk corresponding to a plurality of data elements in an environment. The plurality of data elements may pertain to at least one of a space and a person in the space. The process engine may include at least one of a space risk profiler and a person risk profiler. The process engine may determine a risk score and a risk profile associated with the person and the space. Based on the risk profile, the processor may perform at least one of an automatic identification of a mitigation to reduce the infection risk and an automated generation of an alert.
The invention relates to a method for reproducing in vitro the serine proteinase activity associated with the NS3 protease of hepatitis C virus (HCV), comprising the usage of the containing sequence in NS3 and the containing sequence in NS4A. The NS4 protease of HCV or the other containing sequence is as co-factor of enzyme activity of serine proteinase and generally enzyme activity associated with NS3. When the mol ratio of NS4A and NS3 is at least 1:1, the optimum activity of serine proteinase can be obtained. NS4A and NS3 can also be used as the precursor of NS3-NS4A to incorporate into reactant mixture, because the precursor generates NS4A and NS3 of the same molar weight through proteolysis reaction. The cutting site between NS3 and NS4A is mutated in precursor, thus NS4A combines with NS3 in form of covalent bond. Subsequently the sequence which does not effect the NS3 proteolysis activity is removed from not-proteolysis precursor. The invention also relates to combinations containing the sequence in NS3 and NS4A and an enzyme test of selectively inhibiting the enzymatic activity of compound associated with NS3 using these combinations aim at therapy. The figures show plamid vector for activating NS3 protease of HCV in culture cell ans in vitro.
Participants first received 16 weekly doses of IGSC 20% using a subcutaneous (SC) infusion pump from Week 0 to Week 15. Participants entering study on intravenous immune globulin (IVIG), IGSC 20% was dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) received the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to study entry, without using a dose adjustment factor (DAF). Participants then received 9 biweekly doses of IGSC 20 % (i.e, IGSC 20% every 2 weeks) using an SC infusion pump, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
Stigmasterol is a common dietary phytosterol with high nutritional value and physiological activity. In this study, we evaluated the effects of stigmasterol on inflammatory cytokines and the TGF-β1/Smad2 and IL-17A signaling pathway in an ovalbumin (OVA)-induced asthma mouse model. Stigmasterol treatment improved airway remodeling. In addition, it significantly attenuated the symptoms of asthma attacks, reduced the number of macrophages, lymphocytes, neutrophils, and eosinophils in BALF and inflammatory cytokines, including IL-1β, IL-5, IL-6, and IL-13. It further decreased the level of IL-17A in BALF, serum and spleen. Spleen single-cell suspension analysis via flow cytometry showed that IL-17A level was consistent with the results obtained in BALF, serum and spleen. Stigmasterol decreased the protein expression levels of TGF-β, p-Smad2 and IL-17A in the spleen, by increasing the protein expression level of IL-10. After 24 h of co-culture of TGF-β, IL-6 and stigmasterol, the level of IL-17 in CD4+ T cell supernatant was lower relative to levels in the group without stigmasterol. Meanwhile, stigmasterol treatment attenuated the expression level of TGF- β, p-Smad2 and IL-17A proteins in CD4+ T cells and enhanced the expression levels of IL-10 protein. These data suggested that stigmasterol inhibited the TGF-β1/Smad2 and IL-17A signaling pathway to achieve anti-asthmatic effects in the OVA-induced asthma mouse model. Collectively, the results of this study are that stigmasterol has achieved preliminary efficacy in the non-clinical laboratory, further studies are needed to consider the clinical application of stigmasterol.
Several studies have revealed the risk factors for carpal tunnel syndrome (CTS). However, no studies have evaluated the influence of these risk factors on the selection of treatment modalities for CTS. This study aimed to determine the influence of CTS risk factors on the selection of CTS treatment modalities with a focus on corticosteroid injection (CI) and surgery. We conducted a retrospective cohort study of patients aged ≥20 years with newly diagnosed CTS in the Korean health insurance review and assessment service between 2010 and 2019. We evaluated the demographic information, the existence of CTS risk factors, and the applied treatment modalities for CTS, including CI and operation. The CTS risk factors include age, sex, diabetes mellitus, osteoarthritis of the hand or wrist, rheumatoid arthritis, hypothyroidism, gout, chronic kidney disease (CKD) on dialysis, antiestrogen or aromatase inhibitor medication, and a history of distal radius fracture (DRF). Multivariable logistic regression analyses were conducted. Age over 80 years was the most significantly associated factor for the selection of CI in CTS (odd ratio [OR], 2.149; 95% confidence interval [CI], 2.092 to 2.209; P < .001). Among underlying diseases or medications, CKD on dialysis (OR, 4.001; 95% CI, 3.819-4.193; P < .001) was the most significant associated factor for the selection of operation for CTS, followed by a history of DRF (OR, 1.803; 95% CI, 1.749-1.860; P < .001). Old age was the most significantly related factor for selecting CI. Among underlying diseases or medications, CKD on dialysis and the history of DRF were the most significantly related factors for selecting operative treatment. For these patients, clinicians should proactively consider an operation to reduce the long-term discomfort and economic burdens.
Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
PROBLEM TO BE SOLVED: To obtain a water-soluble vitamin composition useful for foods, pharmaceuticals and cosmetics, capable of stably preserving a water-soluble vitamin therein for a long time and superior in taste by including the water-soluble vitamin, a glycerin fatty acid ester and a neutral lipid. SOLUTION: This composition is obtained by including (A) a water-soluble vitamin (e.g. L-ascorbic acid) in the form of solid particles with an average diameter of pref. <=1 μm, (B) a glycerin fatty acid ester (e.g. polyglycerin condensed ricinoleic acid ester) pref. <=4 in HLB number and (C) a neutral lipid (e.g. medium chain fatty acid triglyceride)(with a melting point of pref. <=45 deg.C in the ratios of A to the whole composition of pref. 15 to 50 wt.% and of B/C of 1 to 100 wt.%. The composition, when dispersed in an aqueous food of e.g. palatable beverage or processed milk product or in an aqueous cosmetic of e.g. cosmetic emulsion, forms a stable W/O/W emulsion system without eluting the water-soluble vitamin contained therein through an emulsification inversion.
The invention relates to the field of medical technology, and concretely relates to a glycopeptide composition as well as a preparation method and an application thereof. The composition comprises the following components in parts by weight: 11-26 parts of enzymolyzed ovalbumin powder, 19-44 parts of enzymolyzed pearl powder, and 30-70 parts of polysaccharides, wherein the polysaccharides comprise animal mucopolysaccharides and/or plant polysaccharides. The preparation method of the glycopeptide composition comprises the following steps: each component is weighed according to the weight part and sieved by an 80 mesh sieve separately, and the components are uniformly mixed. The glycopeptide composition is used for preparing antineoplastic drugs or antineoplastic health products. Enzymolyzed ovalbumin powder, enzymolyzed pearl powder and animal mucopolysaccharide are scientifically compatible for the first time, and a glycopeptide product containing polysaccharides and polypeptides is formed. The polysaccharides and the polypeptides complement each other's advantages for two-way regulation, so that the product can improve immunoregulation function, inhibit tumor, and protect liver. The product has a wide application prospect.
This is a single-center, open-label, self-controlled clinical study with a sample size of 10 patients for 48 weeks, including 24 weeks of administration, and 24 weeks of follow-up. During the administration period, medication was given for 2 weeks and rest for 2 weeks, as a course of treatment, with a total of 6 courses for 24 weeks. During the administration period, the drug was given on alternate days, and IL-2 1mIU was subcutaneously injected the next day for 7 times, and then rested for 2 weeks, and the cycle was repeated for 6 times. The primary outcome index was the change in the rate of ALSFRS-R score between administration period and follow-up period. Secondary outcome measures included changes in the rate of ALSAQ-40 score, ROADS score, MRC score, survival time, FVC%, Treg and CD4+ T cell subsets, inflammatory factors, serum and cerebrospinal fluid NFL during follow-up versus administration , changes in the inhibition function of Treg; Exploratory outcome indicators included the change degree of compound muscle action potential (CMAP) amplitude, quantitative analysis of corneal nerve morphologic changes by corneal confocal microscopy (CCM), Treg single-cell sequencing transcriptome analysis. The related safety indexes were also evaluated.